33 results about "PSMA Antibody" patented technology

The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.

The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.

This invention relates to anti-prostate-specific membrane antigen antibodies (αPSMA) and αPSMA antibody—nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.

The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.

The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and / or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and / or metastasis thereof.

Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.

This invention relates to anti-prostate-specific membrane antigen antibodies (alphaPSMA) and alphaPSMA antibody - nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.

The present disclosure provides antibodies that bind to prostate- specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certainembodiments, the antibodies of the disclosure bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The disclosure includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen- binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen- binding molecules of the disclosure are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and / or therapeutically beneficial. For example, the antibodies of the disclosure are useful for the treatment of various cancers.

Conjugates of an antibody that binds to PSMA with PBD dimers.

The invention provides a kit for detecting prostatic cancer based on liquid biopsy, comprising a staining enhancement solution for enhancing staining effect and specific antibodies with a fluorescent staining marker, wherein the specific antibodies include PSA (prostate specific antigen), CD45 antibody and PSMA (prostate specific membrane antigen); the staining enhancement solution comprises a surfactant having a concentration of 0.001-1 mg / mL. The kit herein is capable of effectively enriching target cells, determining whether the enriched target cells are derived from a patient with early prostatic cancer, and typing CTCs (circulating tumor cells); in addition, double-tumor-marker detection increases detection sensitivity, and detection accuracy is guaranteed through further CEP8 detection; furthermore, the staining effect is enhanced through the staining enhancement solution, each of various antibodies with a fluorescent staining marker can bind with a target cell, the target cells can be stained more effectively, fluorescence is greater, and the boundary is vivid.

The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.

Conjugates of an antibody that binds to PSMA with PBD dimers.

Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.

The invention relates to prostate specific membrane antigen humanized antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates. The invention also relates to methods and compositions for using anti-PSMA antibody drug conjugates in inhibiting, preventing or treating PSMA related diseases or cancers.

This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and / or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

The present invention relates to anti-PSMA antibodies comprising a heavy chain constant region containing one or more amino acid substitutions as compared to wild-type IgG wherein the one or more amino acid substitutions reduce the affinity of the antibody for neonatal Fc receptor (FcRn) as compared to an IgG-based wild-type antibody, thereby reducing the serum half-life of the modified antibody. The one or more amino acid modifications, which have the effect of reducing FcRn binding, are selected from the group consisting of positions His310, His433, His435, His436, Ile253. The antibodies of the invention are particularly suitable for use in radioimmunotherapy.

There is disclosed compositions and methods relating to or derived from anti-PSMA antibodies. More specifically, there is disclosed fully human antibodies that bind PSMA, PSMA-antibody binding fragments and derivatives of such antibodies, and PSMA-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease. There is further disclosed targeted therapies for treatment of prostate cancer having the disclosed anti-PSMA antibodies and fragments thereof targeting the therapeutic agent or cell.

The invention provides a kit for detecting prostatic cancer based on liquid biopsy, comprising a staining enhancement solution for enhancing staining effect and specific antibodies with a fluorescent staining marker, wherein the specific antibodies include PSA (prostate specific antigen), CD45 antibody and PSMA (prostate specific membrane antigen); the staining enhancement solution comprises a surfactant having a concentration of 0.001-1 mg / mL. The kit herein is capable of effectively enriching target cells, determining whether the enriched target cells are derived from a patient with early prostatic cancer, and typing CTCs (circulating tumor cells); in addition, double-tumor-marker detection increases detection sensitivity, and detection accuracy is guaranteed through further CEP8 detection; furthermore, the staining effect is enhanced through the staining enhancement solution, each of various antibodies with a fluorescent staining marker can bind with a target cell, the target cells can be stained more effectively, fluorescence is greater, and the boundary is vivid.